Tag Archives: NYC

RESI NYC 2017 Innovation Challenge – Winners Announced

16 Nov

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newYesterday, we held the Redefining Early Stage Investments (RESI) conference in New York for the first time, and 36 finalists competed for “investment” tokens from the RESI audience. These finalists included companies developing novel drugs or devices, new diagnostics and healthcare IT applications. All of these companies have the potential to revolutionize medicine, but there could only be 3 top prize winners.

First Place: Sen-Jam Pharma

Sen-Jam Pharmaceutical is reimaging health through innovation. Sen-Jam’s Exulta™ asset, a fixed-dose novel combination therapy, provides opioid free pain relief with GI protection for extended use. Exulta™ can stabilize the innate immune system by modulating histamines, prostaglandins and regulating pro-inflammatory cytokines. Exulta™ can also attenuate glial cell activity. Exulta’s platform can be used for multiple indications: reducing opioid induced hyperalgesia, tolerance and dependence for all chronic opioid users, reducing symptoms of opioid withdrawal, treatment of arthritis, reducing common cold symptoms, reducing alcohol hangover symptoms, and preventing symptoms associated with vaccine administration. Exulta™ has been shown in volunteers to reduce symptoms associated with the innate immune response by 60-90% in over 500 dosing events without adverse effects.

Jim Iversen, CEO & COO, Sen-Jam Pharmaceutical | Natasha Eldridge, Director of RESI Conference Series, LSN | Thomas Dahl, Head of Product Development & Regulatory Affairs, Sen-Jam Pharmaceutical | Lucy Parkinson, Director of Investor Research, LSN

Second Place: Bioharmony Therapeutics

Bioharmony Therapeutics is an early-stage biotechnology company developing next-gen antimicrobial therapies for lethal drug-resistant bacterial infections. We are exploiting millions of year of phage-bacteria evolution to develop lysins, enzymes produced by phages that rapidly kill bacteria and have a very low chance of developing resistance. Our lead product targets infections caused by Acinetobacter baumannii, a MDR-pathogen that poses the greatest threat to human health. Our pipeline targets infections caused by other Gram-negative bacteria such as E.coli and Klebsiella, for use in UTI, pneumonia and sepsis.

Chandrabali Ghose, Founder & CEO, Bioharmony Therapeutics | Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN

Third Place: Mirimus

Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. We are a high-tech business unlike any other with expertise in RNAi technologies critical for development of animal models that can pave the way we develop drugs, by pin-pointing potential toxicities and guiding the development of safer, more effective therapeutics. We are revolutionizing the creation of animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms.

Prem Premsrirut, Founder & CEO, Mirimus | Lucy Parkinson, Director of Investor Research, LSN | Natasha Eldridge, Director of RESI Conference Series, LSN

If you missed out on the opportunity to compete in the RESI NYC Innovation Challenge, we’d be happy to take your application for our upcoming San Francisco event on January 9th.

Apply for RESI San Francisco 2018 Innovation Challenge Now!

RESI NYC 2017 – Program Guide Is Here!

9 Nov

By Natasha Eldridge, Director of RESI Conference Series, LSN


We are counting down the days to the first RESI NYC event on November 15th, and it’s now time for LSN to present the RESI NYC 2017 Program Guide. This RESI event draws upon both the rising biotech ecosystem in New York and also LSN’s global network of investors and strategic movers in the life science space, and in the Program Guide, you can find speakers, sponsors, and innovators from all over the world. To check out the full RESI NYC 2017 content and lineup, view the Program Guide below.


Book Your RESI NYC Partnering Meetings Starting on Monday October 23rd

19 Oct

By Natasha Eldridge, Director of RESI Conference Series, LSN


Next Monday, October 23rd, the RESI Partnering Platform will open for the first RESI NYC, and the hundreds of entrepreneurs and investors who are signed up for RESI will have the opportunity to start booking one-on-one meetings.

If you’ve signed up for RESI’s Premier Partnering Plus, you will be able to access deep profiles of investors and strategic players that can be used to ensure you are targeting the most relevant investors in attendance. As well as providing an extra tool to vet the firms you’re reaching out to, Premier Partnering Plus includes contact info to help reach investors and secure meetings. If you’re already registered and would like to talk about upgrading your registration, please contact us at resi@lifesciencenation.com.

Beyond Partnering, RESI will offer 24 panels and workshops featuring more than 100 speakers focused on early-stage investment, and provide an engaging venue for ad-hoc networking on NYC’s up-and-coming biotech scene.

We hope you’re all ready to start filling out your dance card for RESI NYC. The price to attend RESI will increase by $200 after Friday, October 20th – if you’d like to take part in RESI Partnering, don’t delay in signing up.


Look Who’s Coming to RESI NYC

19 Oct

By Lucy Parkinson, Director of Research, LSN

The first RESI NYC event has attracted a great diversity of constituents – from local startups to global investors, from New York-based foundations to major pharma and medtech firms from the Asia region. RESI always aims to draw investors beyond the well-trodden traditional funding tracks of venture capital funds, local angels and pharma; LSN is delighted to have those groups on board too, but at RESI you can also meet family offices, private equity and hedge funds, and the varied investment and strategic groups that participate in our Asia – North America track. Who would you like to meet at RESI NYC? Take a look below at some of the possibilities.

Confirmed Investors and Strategic Partners

As of October 19th, 2017

RESI NYC: Agenda Announced

12 Oct

By Lucy Parkinson, Director of Research, LSN

On November 15th, RESI will come to New York City for the first time ever. As New York’s biotech scene is on the cusp of becoming a major hub, LSN is excited to add RESI as a venue for the city’s emerging biotech and medtech companies to meet with hundreds of global investors.

LSN would now like to announce the agenda for RESI NYC. The event will include 24 investor panels and entrepreneur workshops, including new panels focused on New York biotech and Collaborative Virtual Pharma, and the very first RESI panel of Private Equity & Hedge Funds that invest directly in privately held life science companies. Additionally, a legal workshop will be led by our title sponsor, McDermott Will & Emery. RESI NYC will also feature an updated Asia-North America healthcare investment track, with focus sessions on China Pharma Partners and China Medtech Investors. Check out the full content below. If you want to take part, you can register now.

RESI Boston 2017 Innovation Challenge – Winners Announced NYC Application is Now Open

28 Sep

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newOn Tuesday September 26th, RESI Boston was host to the largest RESI Innovation Challenge yet, with 40 companies competing for the “investment” votes of their fellow attendees. These innovative startups came from across the life science spectrum – develop ing novel products in biotech, medtech, diagnostics and healthcare IT, with the aim of addressing a wide range of different diseases. We hope that all will succeed in bringing their products to patients, but there could only be 3 prize winners. Without further ado, LSN would like to present the top three competitors:

First Place: Wellesley Pharmaceuticals

Nocturia, the frequent need to urinate at night, afflicts 2.3B people, causing insomnia, fatigue, depression, and lower quality of life. It leads to higher rates of heart disease, stroke, brain damage, and deadly falls, killing thousands daily. Wellesley’s Phase 2 trial ended 9/8/17. Results will be unblinded 10/2, but 50% of patients reported >25% nocturia reduction and 27% reported 40-96% benefits, with no side effects. 25% took placebo and 25% reported results averaging 0%. OAB drugs offer 10-15% benefits, bad side effects, and sell $2B/year! Licensing dozens of worldwide patents to big pharma comes next. We expect $10M upfront and 15% of revenue, while they take over all future costs, before launching our drug worldwide. Net margins should approach 95%.

Michael Quigley, VP of Investor Research, Life Science Nation | David Dill, CEO, Wellesley Pharmaceuticals | Dennis Ford, CEO, Life Science Nation

Second Place: Molecular Targeting Technologies

Molecular Targeting Technologies, Inc.’s (MTTI) TDURA is an imaging agent with a unique mechanism to “see” cell death. It is fast, sensitive and enables actionable tracking of cell damage, reducing toxicity,improving survival and minimizing healthcare costs. MTTI has demonstrated proof of efficacy in cardiotoxicity and oncology models. TDURA detected chemotherapy related cardiac dysfunction prior to existing technologies, detected tumor response to therapy as early as 1 day and distinguished responders from non-responders. TDURA is ready for clinical development. Phase II approval for the first indication is projected in 2022. Exit prior to phase III should deliver ≥$100 million value. MTTI has an experienced team, a strong IP and an innovative platform with multiple indications targeted to several unmet medical needs.

Michael Quigley, VP of Investor Research, Life Science Nation | Koon Yan “Chris” Pak, Co-Founder & CEO, Molecular Targeting Technologies, Inc. | Michael Silvon, Senior Vice President of Business Development, Molecular Targeting Technologies, Inc. | Dennis Ford, CEO, Life Science Nation

Third Place: RPS Diagnostics

RPS DIAGNOSTICS is developing FebriDx® for launch outside the USA in 2018. FebriDx is the first and only rapid, in-office test that uses a fingerstick blood sample to help differentiate viral from bacterial acute febrile respiratory infection. The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in 15 minutes, allowing for an effective treatment plan to be established during the patient’s initial office visit.

Michael Quigley, VP of Investor Research, Life Science Nation | Dennis Ford, CEO, Life Science Nation | Doug Lawrence, CEO, RPS Diagnostics

Thank you to all who competed in the RESI Boston Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Apply for RESI NYC Innovation Challenge Now!

McDermott Will & Emery Joins RESI NYC As a Title Sponsor

14 Sep

By Natasha Eldridge, Director of RESI Conference Series, LSN


Life Science Nation (LSN) is proud to announce that McDermott Will & Emery will serve as a title sponsor for the inaugural RESI NYC on November 15, 2017.  McDermott joins RESI NYC title sponsors WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, and Johnson and Johnson Innovation (JLABS), which provides state of the art laboratories, core research facilities, resources and connections to early stage life science innovators.

“We are proud to have been a sponsor of RESI since its inception and are particularly excited to join Wuxi AppTec and JLABS as title sponsors of the inaugural RESI in New York, a burgeoning region for life sciences,” said Byron Kalogerou, founder and chair of the firm’s Life Sciences Industry Group.  “We are continually impressed at the global convening power of RESI in its ability to connect early stage CEOs with the full spectrum of funding sources from VCs, corporate VCs, family offices and sovereign funds to venture philanthropies.  We are excited that many of our early stage clients in our Life Sciences Entrepreneurs Acceleration Program (“LEAP”) will have an opportunity to participate as well.”

“We look forward to sharing our legal insights with RESI attendees in New York in November, and at the September conference in Boston, where we will convene a panel on negotiating term sheets to be led by McDermott Will & Emery attorneys Brian Bunn and Jonathan Ursprung,” said Kalogerou.  “Our new partner, Linda Ji, will moderate the RESI panel on Chinese Investment.”

McDermott Will & Emery offers deep experience in health care and life sciences, and provides a continuum of legal services that will meet the needs of life sciences companies at every stage of development.  The firm’s Life Sciences Industry Group is comprised of 135 professionals, 60 with advanced degrees and many others with government and industry experience across 19 offices around the world.  Learn more here.


%d bloggers like this: